|
Sustained growth in the first half of 2014
2014.08.18
|
|---|
|
Sustained Growth in the First Half of 2014
- Sales up 20.4% and operating profit up 39.8% year-on-year - Rapid improvement of financial structure - Expansion and strengthening of the pharmaceutical local and wholesale divisions - Completion of bio media plant construction
Daehan New Pharm’s growth momentum continued strongly into the first quarter of 2014.
The company recorded total first-quarter sales of 15.67 billion KRW, representing a 20.4% increase compared to the same period last year. Operating profit reached 1.65 billion KRW, up 39.8%, and ordinary profit rose 83.7% to 1.12 billion KRW, demonstrating robust growth and profitability.
By focusing on its core business areas and pursuing profit- and cash flow-centered management, Daehan New Pharm has enhanced business structure quality and growth sustainability. With shorter receivable turnover periods and reduced borrowings, its financial structure continues to improve rapidly. The company’s growth is also being propelled by strengthened leadership in the wellness and beauty sector through differentiated obesity solutions, alongside innovation in distribution structures managing hospitals and clinics directly to secure customer assets and reinforce its distribution network.
To further strengthen its distribution network for sustainable growth, Daehan New Pharm expanded and reorganized its pharmaceutical local and wholesale divisions into independent business units as of March 1. The local division, focused on wellness products, is building relationships with hospitals and clinics, positioning the company as a leading player in this segment. The wholesale division aims to generate synergy with the local division by developing wholesale-exclusive products and nurturing key distributors, evolving into a "Company in Company" model within Daehan New Pharm.
In addition, Daehan New Pharm has completed construction of its bio media plant, establishing a full-scale production system. Test production will be finalized in the second quarter of 2014, after which the company plans to supply customized bio media to clients. Moving forward, Daehan New Pharm will focus on fostering core media and bioprocess products—its next-generation growth engines—laying the foundation for advancement into a leading small-to-mid-sized global biotech company. |


Home